Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 16/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.53 |
| ▸ | FAP | Q12884 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057505 | 0.97 | DPP4 (0.56) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10057507 | 0.92 | DPP4 (0.51) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL14973572 | 0.92 | DPP4 (0.51) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL572058 | 0.87 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL572693 | 0.84 | ACE (0.49) | DPP4DPP8 | |
| SCHEMBL14982904 | 0.84 | ACE (0.49) | DPP4DPP8 | |
| SCHEMBL10056843 | 0.84 | ACE (0.48) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL14973418 | 0.83 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10057509 | 0.81 | DPP4 (0.45) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10057510 | 0.81 | DPP4 (0.54) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600888-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Pharmaceuticals Ltd. (IN) | 2013-06-12 | — | — | EP | claimed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | claimed |
| EP-2600888-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Pharmaceuticals Ltd. (IN) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.